AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
Collaboration brings together Quell™s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca™s proven development and commercial capabilities as...
Under the terms of the agreement, Quell and Cellistic will collaborate in joint research to develop a process for differentiating iPSCs into highly functional Treg cell therapy products. Quell will contribute its Treg expertise and engineering technologies, as well as characterising resulting Treg cells, while Cellistic will be responsible for the iPSC process science and development activities.
Fierce 15 winner Quell Therapeutics has nabbed a huge $156 million series B round for its new-look cell therapy work.
Quell Therapeutics Ltd (Quell), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announced it has entered a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult), an independent centre of excellence to advance the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and full-scale commercialisation.